Please login to the form below

Not currently logged in
Email:
Password:

Leo Pharma calls in Waggener Edstrom

Agency will drive awareness of the pharma company’s anticoagulant in the German market

Leo Pharma has appointed Waggener Edstrom to help drive awareness of its anticoagulant Innohep (tinzaparin) in the German market.

The Munich offices of the communications agency won the account following a competitive pitch process, with the pharma company citing a compelling campaign proposal as a determining factor.

"We are very proud to win an account with a prestigious company like Leo Pharma," said Manuel Hüttl, VP and general manager of Waggener Edstrom Worldwide, Germany, Austria and Switzerland.

"We are looking forward to supporting the Leo Pharma team with the development and execution of innovative, creative and bold strategies."

Since the acquisition of healthcare comms agency Patzer PR in 2012, Waggener Edstrom has been adding names to its list of pharma clients, which includes Astellas, 3M Espe, Berlin Chemie, Medice, AOK Baden-Württemberg and now Leo Pharma.

11th March 2013

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics